GSK, Tsinghua in Infectious Disease Partnership
Friday, July 1, 2016
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said its Beijing-based Institute for Infectious Diseases and Public Health will collaborate with Tsinghua University School of Medicine in a five-year public-private partnership to address public health problems in China. The institute is to invest RMB200 million ($30.1 million) and provide 20 scientists for the collaboration.
GSK said the collaboration will aim to develop treatments for HIV and antibiotic-resistant infections.